Market closed
Avadel Pharmaceuticals/$AVDL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avadel Pharmaceuticals
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Ticker
$AVDL
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Dublin 2, Ireland
Employees
188
Website
AVDL Metrics
BasicAdvanced
$840M
-
-$0.51
-
-
Price and volume
Market cap
$840M
52-week high
$19.09
52-week low
$6.38
Average daily volume
998K
Financial strength
Current ratio
2.748
Quick ratio
2.209
Long term debt to equity
49.251
Total debt to equity
52.599
Interest coverage (TTM)
-3.91%
Management effectiveness
Return on assets (TTM)
-16.11%
Return on equity (TTM)
-60.44%
Valuation
Price to revenue (TTM)
4.892
Price to book
11.36
Price to tangible book (TTM)
14.72
Price to free cash flow (TTM)
-17.636
Growth
Revenue change (TTM)
504.79%
Earnings per share change (TTM)
-74.34%
3-year earnings per share growth (CAGR)
-27.03%
What the Analysts think about AVDL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Avadel Pharmaceuticals stock.
AVDL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AVDL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AVDL News
AllArticlesVideos
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7
GlobeNewsWire·4 days ago
Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
GlobeNewsWire·2 weeks ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Avadel Pharmaceuticals stock?
Avadel Pharmaceuticals (AVDL) has a market cap of $840M as of May 04, 2025.
What is the P/E ratio for Avadel Pharmaceuticals stock?
The price to earnings (P/E) ratio for Avadel Pharmaceuticals (AVDL) stock is 0 as of May 04, 2025.
Does Avadel Pharmaceuticals stock pay dividends?
No, Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders as of May 04, 2025.
When is the next Avadel Pharmaceuticals dividend payment date?
Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders.
What is the beta indicator for Avadel Pharmaceuticals?
Avadel Pharmaceuticals (AVDL) does not currently have a Beta indicator.